Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

AstraZeneca AZ MedImmune Anand SubramonyAstraZeneca's MedImmune unit has appointed Dr Anand Subramony as its new vice president of drug delivery and device development.

He joins the company's biopharmaceutical development unit from Novartis, whose Institutes for Biomedical Research he previously worked for in Cambridge, Massachusetts.

While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group.

Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson & Johnson/Alza Corporation in Mountain View, California.

Dr Subramony will bring to MedImmune experience that includes drug-device combination products and a further boost to its focus on biologics delivery and device development.

13th March 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics